Guo Xingzhi, Liu Yanying, Morgan David, Zhao Li-Ru
1Department of Neurosurgery, State University of New York Upstate Medical University, Syracuse, New York, 13210, USA.
2Translational Neuroscience, Michigan State University, College of Human Medicine, Grand Rapids, Michigan, 49503, USA.
Aging Dis. 2020 Dec 1;11(6):1423-1443. doi: 10.14336/AD.2020.0201. eCollection 2020 Dec.
Alzheimer's disease (AD), characterized by the accumulation of β-amyloid (Aβ) plaques and tau neurofibrillary tangles in the brain, neuroinflammation and neurodegeneration, is the most common form of neurodegenerative disease among the elderly. No effective treatment is available now in restricting the pathological progression of AD. The aim of this study is to determine the therapeutic efficacy of stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF) (SCF+G-CSF) in aged APPswe/PS1dE9 (APP/PS1) mice. SCF+G-CSF was subcutaneously injected for 12 days to 25-month-old male APP/PS1 mice. We observed that SCF+G-CSF treatment reduced the Aβ plaques in both the cortex and hippocampus. SCF+G-CSF treatment increased the association of TREM2/Iba1 cells with Aβ plaques and enhanced Aβ uptake by Iba1 and CD68cells in the brains of aged APP/PS1 mice. Importantly, cerebral expression area of P2RY12and TMEM119 homeostatic microglia and the branches of P2RY12 homeostatic microglia were increased in the SCF+G-CSF-treated aged APP/PS1 mice. SCF+G-CSF treatment also decreased NOS-2 and increased IL-4 in the brains of aged APP/PS1 mice. Moreover, the loss of MAP2dendrites and PSD-95post-synapses and the accumulation of aggregated tau in the brains of aged APP/PS1 mice were ameliorated by SCF+G-CSF treatment. Furthermore, the density of P2RY12 microglia was negatively correlated with Aβ deposits, but positively correlated with the densities of MAP2 dendrites and PSD-95 puncta in the brains of aged APP/PS1 mice. These findings reveal the therapeutic potential of SCF+G-CSF treatment in ameliorating AD pathology at the late stage.
阿尔茨海默病(AD)的特征是大脑中β淀粉样蛋白(Aβ)斑块和tau神经原纤维缠结的积累、神经炎症和神经退行性变,是老年人中最常见的神经退行性疾病形式。目前尚无有效的治疗方法来限制AD的病理进展。本研究的目的是确定干细胞因子(SCF)和粒细胞集落刺激因子(G-CSF)(SCF+G-CSF)对老年APPswe/PS1dE9(APP/PS1)小鼠的治疗效果。将SCF+G-CSF皮下注射给25月龄的雄性APP/PS1小鼠,持续12天。我们观察到,SCF+G-CSF治疗减少了皮质和海马中的Aβ斑块。SCF+G-CSF治疗增加了老年APP/PS1小鼠大脑中TREM2/Iba1细胞与Aβ斑块的关联,并增强了Iba1和CD68细胞对Aβ的摄取。重要的是,在接受SCF+G-CSF治疗的老年APP/PS1小鼠中,P2RY12和TMEM119稳态小胶质细胞的脑表达区域以及P2RY12稳态小胶质细胞的分支增加。SCF+G-CSF治疗还降低了老年APP/PS1小鼠大脑中的NOS-2并增加了IL-4。此外,SCF+G-CSF治疗改善了老年APP/PS1小鼠大脑中MAP2树突和PSD-95突触后膜的丢失以及聚集tau的积累。此外,在老年APP/PS1小鼠大脑中,P2RY12小胶质细胞的密度与Aβ沉积物呈负相关,但与MAP2树突和PSD-95斑点的密度呈正相关。这些发现揭示了SCF+G-CSF治疗在改善晚期AD病理方面的治疗潜力。